These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 26289956

  • 21. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, Park SE, Ma SH, Chang JK, Guitton F, Ortiz E, Kang JH.
    Vaccine; 2011 Feb 11; 29(8):1551-7. PubMed ID: 21215828
    [Abstract] [Full Text] [Related]

  • 22. Community engagement and integrated health and polio immunisation campaigns in conflict-affected areas of Pakistan: a cluster randomised controlled trial.
    Habib MA, Soofi S, Cousens S, Anwar S, Haque NU, Ahmed I, Ali N, Tahir R, Bhutta ZA.
    Lancet Glob Health; 2017 Jun 11; 5(6):e593-e603. PubMed ID: 28495264
    [Abstract] [Full Text] [Related]

  • 23. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
    Miller ER, Moro PL, Cano M, Lewis P, Bryant-Genevier M, Shimabukuro TT.
    Vaccine; 2016 May 27; 34(25):2841-6. PubMed ID: 27087150
    [Abstract] [Full Text] [Related]

  • 24. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
    Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT.
    Clin Infect Dis; 2015 May 15; 60(10):e58-65. PubMed ID: 25637587
    [Abstract] [Full Text] [Related]

  • 25. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT.
    Vaccine; 2018 Mar 20; 36(13):1781-1788. PubMed ID: 29477308
    [Abstract] [Full Text] [Related]

  • 26. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
    Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K.
    Vaccine; 2013 Oct 09; 31(43):4984-7. PubMed ID: 23994022
    [Abstract] [Full Text] [Related]

  • 27. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM, Eriksen E, Lee M, Lee J, Marcy SM, Friedland LR, Weston W, Howe B, Ward JI.
    Pediatrics; 2008 Dec 09; 122(6):e1179-85. PubMed ID: 19047220
    [Abstract] [Full Text] [Related]

  • 28. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL, Hutter GE.
    Ann Pharmacother; 2010 Mar 09; 44(3):515-23. PubMed ID: 20197476
    [Abstract] [Full Text] [Related]

  • 29. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P, Arana J, Pilishvili T, Lewis P, Moro PL, Cano M.
    Vaccine; 2016 Dec 07; 34(50):6330-6334. PubMed ID: 27836437
    [Abstract] [Full Text] [Related]

  • 30. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA.
    Vaccine; 2007 Jan 22; 25(6):1121-5. PubMed ID: 17045366
    [Abstract] [Full Text] [Related]

  • 31. Surveillance of adverse events following vaccination in the French armed forces, 2011-2012.
    Mayet A, Duron S, Meynard JB, Koeck JL, Deparis X, Migliani R.
    Public Health; 2015 Jun 22; 129(6):763-8. PubMed ID: 25890634
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the reactogenicity of three different immunization schedules including diphtheria, tetanus, pertussis, Haemophilus influenza b and polio vaccine in Turkey.
    Beyazova U, Yüksel N, Aksakal FN, Camurdan AD.
    Trans R Soc Trop Med Hyg; 2013 Jul 22; 107(7):438-43. PubMed ID: 23720155
    [Abstract] [Full Text] [Related]

  • 33. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR, Pentacel Study Group.
    Pediatrics; 2009 Jan 22; 123(1):301-12. PubMed ID: 19117896
    [Abstract] [Full Text] [Related]

  • 34. The challenge of changing the inactivated poliomyelitis vaccine in Latin America: declaration of the Latin American Society of Pediatric Infectious Diseases (SLIPE).
    Falleiros-Arlant LH, Avila-Agüero ML, Brea del Castillo J, Mariño C.
    Rev Chilena Infectol; 2014 Oct 22; 31(5):590-603. PubMed ID: 25491459
    [Abstract] [Full Text] [Related]

  • 35. Vaccine safety implications of Ontario, Canada's switch from DTaP-IPV to Tdap-IPV for the pre-school booster.
    Klar S, Harris T, Wong K, Fediurek J, Deeks SL.
    Vaccine; 2014 Nov 12; 32(48):6360-3. PubMed ID: 25252195
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ.
    Vaccine; 2006 May 29; 24(22):4727-36. PubMed ID: 16616973
    [Abstract] [Full Text] [Related]

  • 37. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.
    Cuba IPV Study Collaborative Group.
    N Engl J Med; 2007 Apr 12; 356(15):1536-44. PubMed ID: 17429085
    [Abstract] [Full Text] [Related]

  • 38. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994.
    Braun MM, Ellenberg SS.
    J Pediatr; 1997 Oct 12; 131(4):529-35. PubMed ID: 9386653
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.
    Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS.
    Lancet Infect Dis; 2016 Mar 12; 16(3):321-30. PubMed ID: 26719058
    [Abstract] [Full Text] [Related]

  • 40. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
    Gajdos V, Vidor E, Richard P, Tran C, Sadorge C.
    Vaccine; 2015 Jul 31; 33(32):3988-96. PubMed ID: 26087294
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.